

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

CD127-PE-Vio770, human

RRID:AB_2659856

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-099-719, RRID:AB_2659856

Antibody Information

URL: http://antibodyregistry.org/AB_2659856

Proper Citation: Miltenyi Biotec Cat# 130-099-719, RRID:AB_2659856

Target Antigen: CD127

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 6-2018; Target Distribution B cells, bone marrow, liver, lymphocytes, monocytes, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-412. (RRID:AB_2726160).

Antibody Name: CD127-PE-Vio770, human

Description: This monoclonal targets CD127

Target Organism: non-human primate, human

Clone ID: MB15-18C9

Antibody ID: AB_2659856

Vendor: Miltenyi Biotec

Catalog Number: 130-099-719

Record Creation Time: 20250820T055245+0000

Record Last Update: 20250820T224153+0000

Ratings and Alerts

No rating or validation information has been found for CD127-PE-Vio770, human.

Warning: Discontinued: 2021

Discontinued: 6-2018; Target Distribution B cells, bone marrow, liver, lymphocytes, monocytes, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-412. (RRID:AB_2726160).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen L, et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity, 49(3), 464.